Qinghai Spring Medicinal Resources Technology Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Xuefeng Zhang

Chief executive officer

CN¥568.3k

Total compensation

CEO salary percentage	n/a
CEO tenure	8.9yrs
CEO ownership	n/a
Management average tenure	no data
Board average tenure	3.8yrs

Recent management updates

No updates

Recent updates

Qinghai Spring Medicinal Resources Technology Co., Ltd.'s (SHSE:600381) 27% Price Boost Is Out Of Tune With Revenues

Mar 12

CEO

Xuefeng Zhang (53 yo)

8.9yrs

Tenure

CN¥568,300

Compensation

Board Members

Name	Position	Tenure	Compensation	Ownership
Xuefeng Zhang	Chairman & GM	8.9yrs	CN¥568.30k	no data
Xuemin Gao	Independent Director	3.8yrs	CN¥60.00k	no data
Jin Zhang	Supervisor	1.9yrs	no data	no data

3.8yrs

Average Tenure

Experienced Board: 600381's board of directors are considered experienced (3.8 years average tenure).

Qinghai Spring Medicinal Resources Technology Management

Management criteria checks 3/4

Key information

Recent management updates

Recent updates

Qinghai Spring Medicinal Resources Technology Co., Ltd. (SHSE:600381) announces an Equity Buyback for CNY 50 million worth of its shares.

Qinghai Spring Medicinal Resources Technology Co., Ltd. to Report Q1, 2024 Results on Apr 24, 2024

Qinghai Spring Medicinal Resources Technology Co., Ltd.'s (SHSE:600381) 27% Price Boost Is Out Of Tune With Revenues

Qinghai Spring Medicinal Resources Technology Co., Ltd. to Report Fiscal Year 2023 Results on Apr 24, 2024

Third quarter 2023 earnings released: CN¥0.034 loss per share (vs CN¥0.045 loss in 3Q 2022)

Qinghai Spring Medicinal Resources Technology Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023

Second quarter 2023 earnings released: CN¥0.037 loss per share (vs CN¥0.043 loss in 2Q 2022)

Qinghai Spring Medicinal Resources Technology Co., Ltd. to Report First Half, 2023 Results on Aug 28, 2023

First quarter 2023 earnings released: CN¥0.049 loss per share (vs CN¥0.04 loss in 1Q 2022)

Third quarter 2022 earnings released: CN¥0.045 loss per share (vs CN¥0.017 loss in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.043 loss per share (vs CN¥0.07 loss in 2Q 2021)

Full year 2021 earnings released: CN¥0.42 loss per share (vs CN¥0.54 loss in FY 2020)

Third quarter 2021 earnings released: CN¥0.017 loss per share (vs CN¥0.066 loss in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.07 loss per share (vs CN¥0.08 loss in 2Q 2020)

Full year 2020 earnings released: CN¥0.54 loss per share (vs CN¥0.01 profit in FY 2019)

New 90-day high: CN¥7.12

New 90-day high: CN¥6.86

New 90-day high: CN¥6.24

Hongta Hotland Asset Management Co., Ltd. completed the acquisition of 5.62% stake in Qinghai Spring Medicinal Resources Technology Co., Ltd. (SHSE:600381) from Tibet Rongen Technology Co., Ltd.

Third quarter earnings released

Qinghai Spring Medicinal Resources Technology Co., Ltd. to Report Q3, 2020 Results on Oct 22, 2020

New 90-day low: CN¥4.68

First half earnings released

New 90-day high - CN¥6.00

Qinghai Spring Medicinal Resources Technology Co., Ltd. to Report First Half, 2020 Results on Aug 31, 2020

CEO

Tenure

Compensation

Board Members

Average Tenure